>>C-Type Natriuretic Peptide (CNP) (1-22), human TFA

C-Type Natriuretic Peptide (CNP) (1-22), human TFA

Catalog No.GC63447

C-Type Natriuretic Peptide(CNP)(1-22), 인간(TFA), CNP의 1-22 단편은 나트륨 이뇨 펩티드 수용체 B(NPR-B) 작용제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

C-Type Natriuretic Peptide (CNP) (1-22), human TFA Chemical Structure

Cas No.: 1966153-17-2

Size 가격 재고 수량
500 µg
US$126.00
재고 있음
1 mg
US$198.00
재고 있음
5 mg
US$792.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents

C-Type Natriuretic Peptide (CNP) (1-22), human TFA, exerts its main biological effects by binding to natriuretic peptide receptor B (NPR-B), a membrane-bound guanylyl cyclase receptor that produces cyclic guanosine monophosphate (cGMP). C-Type Natriuretic Peptide (CNP) is a selective agonist of natriuretic peptide receptors NPR-B and C (Kds = 7, and 10.8 pM) [1].

C-Type Natriuretic Peptide (CNP) (1-22), significantly promoted longitudinal bone growth in an organ culture experiment using tibiae from fetal mice [2]. C-Type Natriuretic Peptide (CNP) (1-22) in vivo administration might attenuate cardiac remodeling after myocardial infarction (MI) through its antifibrotic and antihypertrophic action [3]. NPR-B-mediated cGMP production after CNP administration specifically acted on the pylorus, colon, and rectum and contributed to gastric emptying [1].

References:
[1]: Sogawa C, Wakizaka H, Aung W, Jin ZH, Tsuji AB, Furukawa T, et al. C-type natriuretic peptide specifically acts on the pylorus and large intestine in mouse gastrointestinal tract. Am J Pathol. 2013;182:172-9.
[2]. Yasoda A, Ogawa Y, Suda M, Tamura N, Mori K, Sakuma Y, Chusho H, Shiota K, Tanaka K, Nakao K (1998) Natriuretic peptide regulation of endochondral ossification. Evidence for possible roles of the C-type natriuretic peptide/guanylyl cyclase-B pathway. J Biol Chem 273:11 695-11 700
[3]. Soeki T, Kishimoto I, Okumura H, Tokudome T, Horio T, Mori K, Kangawa K. C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. 2005.J Am Coll Cardiol 45:608-616

리뷰

Review for C-Type Natriuretic Peptide (CNP) (1-22), human TFA

Average Rating: 5 ★★★★★ (Based on Reviews and 26 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for C-Type Natriuretic Peptide (CNP) (1-22), human TFA

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.